Trial · NCT02193776
Participant flow20
How many started, completed or left each group, period by period.
1 to 20 of 20
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | DS-TB: Bedaquiline (Loading Dose/t.i.w)+ PA-824 + Pyrazinamide | 59 | |
| Overall Study | STARTED | DS-TB: Bedaquiline (200 mg) + PA-824 + Pyrazinamide | 60 | |
| Overall Study | STARTED | DS-TB: HRZE (Isoniazid+Rifampicin+Pyrazinamide+Ethambutol) | 61 | |
| Overall Study | STARTED | MDR-TB: Bedaquiline (200 mg)+Moxifloxacin+PA-824+Pyrazinamide | 60 | |
| Overall Study | Completed Day 70 Follow-up | DS-TB: Bedaquiline (Loading Dose/t.i.w)+ PA-824 + Pyrazinamide | 54 | |
| Overall Study | Completed Day 70 Follow-up | DS-TB: Bedaquiline (200 mg) + PA-824 + Pyrazinamide | 56 | |
| Overall Study | Completed Day 70 Follow-up | DS-TB: HRZE (Isoniazid+Rifampicin+Pyrazinamide+Ethambutol) | 60 | |
| Overall Study | Completed Day 70 Follow-up | MDR-TB: Bedaquiline (200 mg)+Moxifloxacin+PA-824+Pyrazinamide | 60 | |
| Overall Study | Completed Day 140 Follow-up | DS-TB: Bedaquiline (Loading Dose/t.i.w)+ PA-824 + Pyrazinamide | 52 | |
| Overall Study | Completed Day 140 Follow-up | DS-TB: Bedaquiline (200 mg) + PA-824 + Pyrazinamide | 52 | |
| Overall Study | Completed Day 140 Follow-up | DS-TB: HRZE (Isoniazid+Rifampicin+Pyrazinamide+Ethambutol) | 58 | |
| Overall Study | Completed Day 140 Follow-up | MDR-TB: Bedaquiline (200 mg)+Moxifloxacin+PA-824+Pyrazinamide | 58 | |
| Overall Study | COMPLETED | DS-TB: Bedaquiline (Loading Dose/t.i.w)+ PA-824 + Pyrazinamide | 51 | |
| Overall Study | COMPLETED | DS-TB: Bedaquiline (200 mg) + PA-824 + Pyrazinamide | 53 | |
| Overall Study | COMPLETED | DS-TB: HRZE (Isoniazid+Rifampicin+Pyrazinamide+Ethambutol) | 59 | |
| Overall Study | COMPLETED | MDR-TB: Bedaquiline (200 mg)+Moxifloxacin+PA-824+Pyrazinamide | 58 | |
| Overall Study | NOT COMPLETED | DS-TB: Bedaquiline (Loading Dose/t.i.w)+ PA-824 + Pyrazinamide | 8 | |
| Overall Study | NOT COMPLETED | DS-TB: Bedaquiline (200 mg) + PA-824 + Pyrazinamide | 7 | |
| Overall Study | NOT COMPLETED | DS-TB: HRZE (Isoniazid+Rifampicin+Pyrazinamide+Ethambutol) | 2 | |
| Overall Study | NOT COMPLETED | MDR-TB: Bedaquiline (200 mg)+Moxifloxacin+PA-824+Pyrazinamide | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02193776/flow